Department of Hematology
The Hematology Department at Gustave Roussy treats blood and bone marrow cancers in adults. Its specialized teams support patients at every stage of their care journey, from diagnosis to the most innovative treatments, drawing on recognized expertise, cutting-edge research, and a multidisciplinary approach.
The department’s physicians work closely with clinical laboratory teams specializing in hematology, as well as with other departments at Gustave Roussy.
This organizational structure enables the department to offer each patient personalized care, based on the most recent international guidelines and access to therapeutic innovations.
Department
Chair: Prof. Stéphane de Botton
Key Figures
-
4
inpatient units
-
1
13-bed outpatient clinic
-
46
hospital beds
-
1
outpatient department
Conditions Treated
Myeloid Hematologic Disorders
- Acute and Chronic Myeloid Leukemias
- Myeloproliferative syndromes
- Myeloproliferative syndromes
- Mixed myelodysplastic and myeloproliferative disorders
Lymphoid blood disorders
- Acute and chronic lymphoid leukemias
- Non-Hodgkin lymphomas
- Hodgkin's disease
- Multiple myeloma
What is a malignant blood disorder?
Malignant hematologic diseases are cancers that affect the cells of the blood, bone marrow, or lymphatic system. They include, in particular, leukemias, lymphomas, and myelomas.
Department Organization
Outpatient Hospital
- 13 beds
- Ground floor of the Institute
Secured Intensive Care Units
Paris D4
- 11 beds
- 8th floor
Paris D3
- 11 beds
- 8th floor
Suzanne Axel
- 12 beds
- 8th floor
Manche
- 12 beds
- 8th floor
Research and Innovation
Innovative Treatments Available to Our Patients
The goal of the department’s research program is to offer each patient the best available treatment options, including innovative treatments currently under evaluation when they are appropriate for the patient’s situation.
The studies offered comply with a strict regulatory framework and always require the patient’s consent.
Participate in the research
Phase III clinical trials
A comparison of a standard-of-care treatment with a new therapeutic strategy that has shown promising preliminary results.
Phase I and II clinical trials
Proposal of innovative treatments when standard treatments have not yielded the expected results, in collaboration with DITEP.
Non-therapeutic studies
Additional blood or bone marrow samples collected to advance scientific understanding of hematologic diseases.
Patient Rights
All research is approved by the relevant authorities and an ethics committee. Participation is voluntary and may be discontinued at any time.
Our Major Areas of Research
Development of new targeted therapies, particularly those targeting mutations in the IDH1 and IDH2 genes.
Research on Vaquez disease, essential thrombocythemia, and myelofibrosis.
Study of the biological mechanisms involved in this disease and in myelodysplastic syndromes.
Research on the genetic and epigenetic factors that contribute to the development of malignant hematologic disorders.
Education and Training
The department's physicians participate in the training of medical students at Paris-Saclay University and regularly host interns and students in training.
The teams are also involved in postgraduate education and in training programs for French and international healthcare professionals.
Department officials
- Prof. Stéphane de Botton, Chair of the Department of Hematology, Chair of the Hematology Committee (110), and Director of Myeloid Pathology
- Prof. Catherine Thieblemont, Head of Lymphoid Pathology
- Dr. Cristina Castilla-Llorente, Head of the Cell Therapy Program
- Dr. Vincent Ribrag, Early-Phase Trials
- Sandrine Baroux, Care Coordinator
- Miguel Maiz, Deputy Director of Management
- Nathalie Anne, Administrative Manager
Contacts
Hematology Clinic
Phone reception for new patients and medical emergencies only (9 a.m.–5 p.m.):
Tel.: +33 (0)1 42 11 67 15
Fax: +33 (0)1 42 11 52 70
Transplant - Pre-transplant evaluation coordination:
+33 (0)1 42 11 42 39